Healthy
Conditions
Keywords
Healthy, Male, Canagliflozin (JNJ-28431754), Radiolabeled 14C-canagliflozin, Absorption, Metabolism, Excretion, Radioactivity
Brief summary
The purpose of this study is to investigate the absorption (the way the drug enters the body), metabolism (the way the drug is broken down in the body), and excretion (the way drug leaves the body) of canagliflozin (JNJ-28431754) in healthy male volunteers after a single dose of radiolabeled 14C-canagliflozin (14C-JNJ-28431754). The safety and tolerability of canagliflozin will also be assessed.
Detailed description
This study will be an open label (all volunteers and study staff know the identity of the assigned treatment), single dose, single center study to investigate the absorption, metabolism, and excretion of canagliflozin (a drug currently being investigated for the treatment of type 2 diabetes mellitus). The study will consist of 3 phases: a screening phase, an open-label treatment phase, and an end-of study (or follow-up) phase. On Day 1, all volunteers will receive a single oral dose of radiolabeled 14C-canagliflozin which contains 196 mg of canagliflozin and approximately 40 microcurie (1480kBq) of radioactivity. The International Commission on Radiological Protection considers this amount of radioactivity to be acceptable for this type of study. The radioactivity allows the amount of canagliflozin and its metabolites (break-down products) to be more precisely measured in blood, plasma, urine, and feces samples, which will be collected from each volunteer. The total duration of the study is approximately 5 weeks (including screening and follow-up); this time will be increased by 6 days in volunteers who have a slower rate of excretion of canagliflozin.
Interventions
DRUGRadiolabelled 14C-canagliflozin (14C-JNJ-28431754)
A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Body Mass Index (BMI) (weight \[kg\]/height \[m2\]) between 18 and 30 kg/m2 * Non-smoker
Exclusion criteria
* Exposure to radiation for professional or medical reasons (except dental x-rays and x-rays of thorax and bone skeleton, excluding spinal column) in the past 12 months * History of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of canagliflozin (JNJ-28431754) metabolites in feces | Up to Day 14 | Concentrations of canagliflozin (JNJ-28431754) metabolites in feces will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body). |
| Plasma concentrations of canagliflozin (JNJ-28431754) | Up to Day 3 | Plasma concentrations of canagliflozin (JNJ-28431754) will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug). |
| Urine concentrations of canagliflozin (JNJ-28431754) | Up to Day 14 | Urine concentrations of canagliflozin (JNJ-28431754) will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug). |
| Total radioactivity of 14C-canagliflozin (14C-JNJ-28431754) excreted in urine | up to Day 14 | The total radioactivity excreted in the urine will be expressed as a percentage of the administered dose of canagliflozin (JNJ-28431754) and will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug). |
| Total radioactivity of 14C-canagliflozin (14C-JNJ-28431754) excreted in feces | Up to Day 14 | The total radioactivity excreted in the feces will be expressed as a percentage of the administered dose of canagliflozin (JNJ-28431754) and will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug). |
| Total radioactivity of 14C-canagliflozin (14C-JNJ-28431754) in blood | Up to Day 8 | The total radioactivity in blood will be used to determine pharmacokinetic parameters for canagliflozin (JNJ-28431754) (measurements describing how the body affects the drug). |
| Total radioactivity of 14C-canagliflozin (14C-JNJ-28431754) in plasma | Up to Day 8 | The total radioactivity in plasma will be used to determine pharmacokinetic parameters for canagliflozin (JNJ-28431754) (measurements describing how the body affects the drug). |
| Concentrations of canagliflozin (JNJ-28431754) metabolites in plasma | Up to Day 14 | Concentrations of canagliflozin (JNJ-28431754) metabolites in plasma will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body). |
| Concentrations of canagliflozin (JNJ-28431754) metabolites in urine | Up to Day 14 | Concentrations of canagliflozin (JNJ-28431754) metabolites in urine will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body). |
Secondary
| Measure | Time frame |
|---|---|
| Number of volunteers with adverse events as a measure of safety and tolerability | up to 5 weeks |
Countries
Belgium
Outcome results
None listed